euro adhoc: Intercell AG / Annual Reports / Intercell AG announces Q2/ H1 2008 results and gives update on business

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

6-month report

18.08.2008

» International approval processes for Japanese Encephalitis vaccine
on schedule - Approvals of Intercell´s Japanese Encephalitis vaccine
candidate in the US, Europe and Australia expected within the next
few months

» Acquisition of Iomai Corporation (Iomai) closed according to plan

» Despite higher costs because of Iomai acquisition profitability
expected for full year 2008

» Revenues increased to EUR 17.6 m in H1 2008 compared EUR 5.2 m in
H1 2007 (240.3 percent) - Net loss decreased by EUR 6.9 m (44.4
percent), to EUR 8.6 m in H1 2008 from EUR 15.6 m in H1 2007 -
Strong cash position with EUR 258.3 m by the end of H1 2008

Vienna (Austria), August 18, 2008 - Today Intercell AG (VSE: ICLL)
announced the financial results for Q2 / H1 2008 and released an
update on the company´s developmental programs and strategy.

Following the completion of US FDA pre-approval inspection, Intercell
continues to work towards approvals of its Japanese Encephalitis
vaccine candidate in the US, Europe and Australia within the next few
months

» FDA waives VRPAC (Vaccines and Related Biological Products Advisory
Committee); pre-approval inspection completed on time

» Licensure application submitted to Australian Therapeutic Goods
Administration (TGA) and to Canadian Division of Biologics and
Genetic Therapies Directorate of Health. TGA grants priority review
for Intercell's vaccine candidate in Australia

» Intercell already produces the vaccine at its manufacturing
facility in Livingston under the commercial Manufacturer's License
from MHRA

» Vaccine demonstrates excellent safety and immunogenicity at "half
dose" in Phase II trials in children. Development for endemic
markets with Intercell's Indian partner Biological E. progresses
well

» Ongoing strategic assessment of potential opportunities on the
Japanese market continues

Intercell acquires Iomai and strengthens leadership in vaccine
innovation - first focusing on bringing the vaccine patch for
Traveler's Diarrhea to market

» Intercell's acquisition of Iomai closed smoothly on August 5, 2008.
The total consideration of 1,442,819 Intercell shares and a cash
component of EUR 75 million (USD 116 million), was comfortably
financed from existing reserves

» Valuable expansion of Intercell's pipeline and leveraging of
Intercell's late-stage product development with two further
programs in late-stage clinical development - the vaccine patch for
Traveler's Diarrhea (start of Phase III planned for the first half
of 2009) and the vaccine enhancement patch for the Pandemic Flu
(start of Phase II in 2008)

Hospital-acquired infections - all developmental programs on track

» S. aureus: Phase II of the vaccine in elective cardiothoracic
surgery - conducted by Merck & Co - progressing (conducted by Merck
& Co., Inc.)

» Pseudomonas: Start of clinical Phase II/III trials expected for
2008

» Pneumococcus: Outstanding pre-clinical results on the novel,
protein-based, universal vaccine published in the Journal of
Experimental Medicine; initiation of Phase I trials planned for
2008

Adjuvant IC31® - Progress in the development of new Influenza vaccine
- Sanofi Pasteur joins Tuberculosis cooperation

» Influenza: Novartis initiated clinical trials for the seasonal flu
vaccine containing IC31®

» Tuberculosis: The tuberculosis vaccine, currently being tested in
clinical trials (formulated with IC31®), will be further developed
in a partnership between Statens Serum Institut (SSI) and Sanofi
Pasteur

Financial Statement

» Revenues increased to EUR 17.6 m in H1 2008 compared EUR 5.2 m in
H1 2007, or by 240.3 percent. Net loss decreased by EUR 6.9 m, or
by 44.4 percent, to EUR 8.6 m in H1 2008 from EUR 15.6 m in H1
2007. Strong cash position with EUR 258.3 m by the end of H1 2008

Management Board

» Intercell's CSO, Alexander von Gabain, appointed to the Governing
Board of the European Institute of Innovation and Technology

KEY FIGURES

in EUR thousands 3 months 6 months Year
ended ended ended
June 30, June 30, Dec 31,
2008 2007 2008 2007 2007

Revenues 9,018 3,682 17,642 5,184 53,349

Net profit/(loss) (4,032) (8,522) (8,650) (15,571) 5,009

Net operating
cash flow (12,578) (4,867) (25,386) (14,502) (41,686)

Cash and marketable
securities,
end of period 258,286 81,056 258,268 81,056 257,571

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Intercell AG

Lucia Malfent

Head of Communications

Tel. +43 1 20620-303

lmalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wiener Börse AG / official market